Jynarque
Ended Awarded Last action
- Contract number
- 36C26223F0477
- Awardee
-
Otsuka America Pharmaceutical Inc. UEI QKABLBMA8FT9
- Awarding agency
-
Veterans Integrated Service Network 22
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $284,695
Award facts
- Contract value 100% obligated
- $284,695.42 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Pittsburgh, PA 15275, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | -$8,117 | |
| Original award | $292,813 |
About this award
On July 1, 2023, the Department of Veterans Affairs (VA), specifically Veterans Integrated Service Network 22, awarded a delivery order to Otsuka America Pharmaceutical Inc. for Jynarque (tolvaptan) with a ceiling value of $284,695.42. This firm fixed-price delivery order, with an ultimate completion date of June 30, 2024, was issued without set-aside designation under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The contract supports the VA's provision of specialty pharmaceuticals to veterans, with performance taking place in Pittsburgh, Pennsylvania.
Otsuka America Pharmaceutical Inc., a for-profit pharmaceutical manufacturer headquartered in Rockville, Maryland, is a primary supplier of Jynarque to the VA's Veterans Health Administration. This delivery order represents one of multiple procurement actions the company fulfills under its larger Indefinite Delivery Vehicle agreements with the VA, including a significant $83.3 billion Blanket Purchase Agreement for Jynarque awarded by the National Acquisition Center and scheduled for completion in March 2026. These contracts enable VA facilities across multiple Integrated Service Networks to efficiently procure medications for treating autosomal dominant polycystic kidney disease and hyponatremia for eligible veterans nationwide.
Quick answers
Who was awarded contract 36C26223F0477?
36C26223F0477 was awarded to Otsuka America Pharmaceutical Inc. by Veterans Integrated Service Network 22 (Veterans Health Administration) on July 1, 2023.
How much is contract 36C26223F0477 worth?
The government has obligated $284,695 on 36C26223F0477.
Is contract 36C26223F0477 an order under another contract?
Yes. 36C26223F0477 is a delivery order under 36F79720D0099, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C26223F0477 competed?
The extent of competition for 36C26223F0477 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award